Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

GenMont Biotech, Inc. (3164) AI Stock Analysis

TW:3164

GenMont Biotech, Inc.

(TWSE:3164)

Select Model
Rating:71Outperform
Price Target:TWD 18.50â–²(10.45% Upside)
Action:initiatedcoverage
Date:11/10/26

The score is supported primarily by strong profitability and financial stability. Declining cash-flow momentum and limited returns on equity weigh on the financial outlook, while mixed technical signals and only moderately attractive valuation constrain the overall assessment.

Positive Factors
Conservative balance sheetLow leverage and a large equity base provide resilience and financial flexibility. With debt of about 110M against roughly 1.33B of equity, GenMont can absorb operating volatility and retain capacity to fund development without heavy reliance on borrowing.
Negative Factors
Volatile revenue growthThe uneven revenue path reduces visibility into GenMont’s growth trajectory. A rebound in 2025 is encouraging, but prior declines and the reported negative growth measure indicate that demand and commercialization progress have not yet formed a consistently expanding trend.

GenMont Biotech, Inc. (3164) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%TW:3164-5.41%SPY+12.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 1.42B
Dividend Yield
4.78%
Average Volume (3M)
37.49K
Price to Earnings (P/E)
20.7
Beta (1Y)
0.16
Revenue Growth
1.32%
EPS Growth
80.16%
Country
TW
Employees
147
Sector
General
Sector Strength
55
Industry
Biotechnology

GenMont Biotech, Inc. Business Overview & Revenue Model

Company Description

Based in Taiwan, GenMont Biotech Incorporation is primarily engaged in the comprehensive process of developing, manufacturing, and marketing functional probiotic products. Beyond its core offerings, the company also provides specialized probiotic for...

GenMont Biotech, Inc. Financial Statement Overview

Summary

Strong balance-sheet stability and profitability support the score, while declining operating and free cash flow, modest net-income growth, and low return on equity limit upside.

Income Statement

78Positive

Balance Sheet

91Very Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue382.11M401.23M385.37M318.01M368.55M427.93M
Gross Profit227.50M251.63M238.18M211.19M256.72M299.33M
EBITDA116.68M124.57M140.03M93.92M117.43M161.29M
Net Income69.17M57.20M57.25M32.99M56.98M113.13M
Balance Sheet
Total Assets1.67B1.67B1.71B1.65B1.70B1.70B
Cash, Cash Equivalents and Short-Term Investments354.63M432.80M425.81M328.30M400.94M421.73M
Total Debt125.85M110.31M118.61M58.31M34.55M32.73M
Total Liabilities241.98M215.35M229.06M204.06M198.59M173.65M
Stockholders Equity1.31B1.33B1.35B1.32B1.35B1.38B
Cash Flow
Free Cash Flow85.27M69.94M79.67M-941.00K66.04M-5.46M
Operating Cash Flow86.59M73.60M123.95M34.60M136.98M111.66M
Investing Cash Flow9.31M7.70M-82.42M-75.37M-82.73M-153.07M
Financing Cash Flow-66.53M-88.64M12.55M-36.82M-91.08M-61.37M

GenMont Biotech, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:3164 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:3164TW:316471OutperformTWD 1.44B20.68―4.78%1.32%80.16%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:6846TW:684655NeutralTWD 1.33B10.22―8.05%-3.09%-27.22%
TW:4127TW:412740UnderperformTWD 1.65B23.58――52.12%―
TW:6431TW:643138UnderperformTWD 1.45B-7.50――-14.57%13.16%

* General Sector Average

Performance Comparison

0%50%100%150%TW:3164TW:4127TW:6431TW:6846TW:6886TW:7806Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:3164 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:3164GenMont Biotech, Inc.16.75-0.96-5.41%
TW:4127Tien Liang Biotech Co., Ltd.36.154.4013.86%
TW:6431Kuangli Bio-Tech Holdings Co., Ltd.14.85-1.45-8.90%
TW:6846Greenyn Biotechnology Co., Ltd.49.00-24.13-32.99%
TW:6886Far East Bio-Tec. Co., Ltd.38.65-2.71-6.56%
TW:7806Gin Hwa Biotech, Inc.49.40-9.82-16.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026